In the United States, Fast Track designation is granted to help expedite drug development and review for serious, rare, or life-threatening conditions. To receive Fast Track designation, the treatment must…
In mid-August 2021, Parkinson's News Today reported that dosing was complete in a Phase 2a clinical trial. During the trial, researchers were evaluated ANVS401, an investigational compound for patients…
In a recent news release, biopharmaceutical company Retrotope shared that enrollment was complete in its Phase 2 clinical trial. During the trial, researchers will evaluate RT001, a first-in-class oral…
In mid-July 2021, biotechnology company Alterity Therapeutics ("Alterity") shared the publication of new data regarding ATH434 for patients with multiple system atrophy (MSA). The data comes from a preclinical…
It's no secret that illicit substance use, or substance use disorders, can cause a variety of health effects, including increased risks for certain diseases. As Parkinson's News Today recently reported,…
Initially, biopharmaceutical company Anavex Life Sciences ("Anavex") developed Anavex 2-73 (blarcamesine) for patients with Alzheimer's disease. Now, the company has expanded its exploration of the therapy to determine its efficacy…
In the past, antipsychotics were recommended as a potential treatment for patients with Parkinson's disease (PD). This is because, in later stages of PD, patients may experience Parkinson's psychosis, which…
Impel NeuroPharma has been working on a campaign focused on migraines. It is called Reroute Migraine Relief, and it was built in coordination with an artist who suffers from migraines…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
